SynthesisPsycho-oncology2025
Understanding the Trajectory of Depressive Symptoms in Newly Diagnosed High-Grade Glioma Patients-A Meta-Analysis.
Synthesis in Psycho-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionHigh-grade gliomas, the most common and aggressive brain cancer, are associated with significant neurological disability and are almost uniformly fatal. Though the diagnosis of brain cancer is represented as one of the most stressful life events for patients as well as for their caregivers, the prevalence of depression as a longitudinal event during and after the initial diagnosis and sequential lines of treatment is under-researched.
objectivesTo inform clinical practice, we assembled published, time-specific estimates of the prevalence of depression in adult high-grade glioma patients to test the idea that depression prevalence varies across therapeutic trajectory milestones.
methodsWe a priori defined five time points in the clinical course of first-line therapy. After an exhaustive search of the current literature, we extracted time point-specific estimates of depression prevalence, pooled the data by time point across studies, and constructed 95% confidence intervals on depression prevalence at each time point. A total of 822 patients were identified and entered into our analyses.
resultsThe prevalence of depression in adult high-grade glioma is about 16%-27% between surgery and the end of temozolomide maintenance therapy, which is higher than the 9% estimated for the general population. However, when assessed in the time interval between the initial diagnostic tumor imaging and the confirmatory surgery, at least 30% of these patients are depressed.
conclusionsBecause depression worsens the patient's quality of life and is treatable, the multidisciplinary treatment teams involved in the care of high-grade glioma patients should assess depression throughout the disease trajectory, and especially immediately after the first imaging study showing a suspicious intracranial mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.